Biogen (BIIB) PT Lowered to $390 at Goldman Sachs
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $221.12 +4.03%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Terence Flynn lowered the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $436.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Target (TGT) PT Raised to $185 at DA Davidson
- Legence Corp (LGN) PT Raised to $130 at Tigress Financial Partners
- Palo Alto Networks (PANW) PT Raised to $390 at UBS, Neutral Rating Maintained
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
